ArticleVeterinary research2026
Molecular mechanism of Tembusu virus nonstructural protein 5 antagonising RNA interference.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Tembusu virus (TMUV), a member of the genus Orthoflavivirus within the family Flaviviridae, is an emerging pathogen that severely impacts waterfowl, causing decreased egg production in laying ducks and neurological symptoms in ducklings and growing birds. RNA interference (RNAi) is a conserved post-transcriptional regulatory mechanism mediated by small non-coding RNAs in eukaryotic cells, while many viruses can antagonise host RNAi-mediated antiviral immunity by encoding viral suppressors of RNAi (VSRs). In this study, we demonstrated that TMUV antagonises the RNAi pathway. Using enhanced green fluorescent protein (EGFP)-based RNAi reporter systems in both HEK293T and Drosophila S2 cells, we identified the TMUV nonstructural protein 5 (NS5) as a potent VSR. Furthermore, we found that NS5 not only interacts with DEAD-box helicase 3 X-linked (DDX3X), a key protein in the RNAi pathway, but also binds directly to double-stranded RNA (dsRNA). In summary, our findings indicated that TMUV NS5 can act as a VSR in vitro, thereby providing a theoretical foundation for the development of antiviral therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.